This study provides evidence to assist the future stratification of TNBC patients, to ensure that poor-outcome TNBCs can be identified earlier, and suggests that the use of Slug and TGFβ2 modulators could be included in future as part of a treatment regimen for poor-outcome TNBC, to improve the poor survival outcomes associated with this highly aggressive subtype of breast cancer. The gene discussed is TGFB2; the disease is breast cancer.